Infectious complications associated with the use of tumor necrosis factor antagonist drugs: A review;Complicaciones infecciosas asociadas al uso de fármacos antagonistas del factor de necrosis tumoral. Revisión de conjunto

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 9, 2005, Pages 551-559

  García Lechuz Moya, Juan M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Biological therapies; Etanercept; Infectious complications; Infliximab; Review; Tuberculosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

BACTERIAL INFECTION; DRUG INDICATION; FOLLOW UP; HUMAN; INFECTION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; LYMPHOPROLIFERATIVE DISEASE; NEUROLOGIC DISEASE; RASH; REVIEW; RHEUMATOLOGY; TUBERCULOSIS;

EID: 28144449976     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13080266     Document Type: Review

References (67)

1. O'Sullivan JB, Cathcart ES. The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med. 1972;76:573-7.
2. Scott D, Symmons D, Coulton B, Popert A. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;2:1108-11.
3. O'Dell JR. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat. Mayo Clin Proc. 2001;76:573-5.
4. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol. 1996;35:781-90.
5. Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994;76:275-85.
6. Playfair JHL. Immunology at a glance. 6th ed. Cambridge: Blackwell Scientific Publications; 1996.
7. Janeway CA, Travers P, Walport M, Capra JD. Immunobiology: the immune system in health and disease. 4th ed. Barcelona: Masson; 2000.
8. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol. 1993;10:561-91.
9. Preas HL, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184:373-6.
10. Lamping N, Dettmer R, Schroder NW, Pfiel D, Hallatschek W, Burger R, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest. 1998;101:2065-71.
11. Pfieffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457-67.
12. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf). 2001;54:347-54.
13. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16.
14. Koh ET. New disease modifying agents in adult rheumatoid arthritis. Ann Acad Med Singapore. 2001;30:170-3.
15. Spencer-Green G. Etanercept (Enbrel®): update on therapeutic use. Ann Rheum Dis. 2000;59:146-9.
16. Hamilton K, Clair EW. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother. 2000;1:1041-52.
17. Zhou H, Daniels JL, Longnecker MP, Klebanoff MA, Gray KA, Brock JW, et al. Pharmacokinetics (PK) of etanercept are unaltered by concurrent administration of methotrexate (MTX) in rheumatoid arthritis (RA) (Abstract 253). Arthritis Rheum. 2003;48:S139.
18. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys E. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor-alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000;59:428-33.
19. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-9.
20. Brandt J, Haibel H, Cornely D, Golder W, González J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor-alpha monoclonal antibody infliximab. Arthritis Rheum. 2000; 43:1346-52.
21. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13 Suppl 4:16-22; discussion 38.
22. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443-53.
23. Scallon B, Cai A, Solowski N, Germain B, Laffon A, Jacobs J, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418-26.
24. Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc. 2000;75:1093-8.
25. Fautrel B, Cherin P. Value of anti-TNF-alpha molecules in inflammatory and infectious diseases. Rev Med Interna. 2000;21:872-88.
26. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59:1341-59.
27. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 2000;50:229-35.
28. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149-54.
29. Mohan VP, Scanga CA, Yu K, Flynn JL, Goldstein MM, Chan J, et al. Demyelinizating effects of etanercept therapy. Arthritis Rheum. 2001;44:2862-9.
30. Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum. 1991;21:1-11.
31. Lang B, Riegel W, Peters T, Le Mense GP, Sahn SA, Flood DA, et al. Low dose methotrexate therapy for rheumatoid arthritis complicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol. 1991;18:1257-9.
32. Bouza E, Prevention of infections related to anti-TNF treatments. Rev Esp Reumatol. 2001;28:84-5.
33. García-Lechuz J, Bouza E. Infectious complications in rheumatoid arthritis. Rev Clin Esp. 2000;200:59-63.
34. Le Mense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med. 1994;150:258-60.
35. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun. 1997;65:298-304.
36. Mohan VP, Scanga CA, Yu K, Flynn JL, Goldstein MM, Chan J, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001; 69:1847-55.
37. Flynn JL, Goldstein MM, Chan J, Scanga CA, Mohan VP, Yu K, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561-72.
38. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol. 2000; 164:2016-20.
39. Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treatment asthmatic population. Ann Intern Med. 1976;84:261-5.
40. Kim HA, Yoo CD, Baek HJ, Kunske R, Schatz M, Patterson R, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998;16:9-13.
41. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med. 2001;345:1098-104.
42. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5.
43. FDA Meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part II: safety and Efficacy Update on TNF alpha inhibitors; Humira (adalimumab), Remicade (infliximab) and Enbrel (etanercept). Washington DC, March 4, 2003; p. 2-233. Disponible en: www.fda.gov/OHRMS/DOCKETS/98fr/03-4350. html
44. Mohan A, Coté T, Block J, Manadan A, Siegel J, Braun M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295-9.
45. Ehlers S, Benini J, Kutsch S, Ghrayeb J, Kalden J, Malvem S, et al. Fatal granuloma necrosis without exacerbated mycobacterial growth in TNF receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun. 1999;67:3571-9.
46. Jacobs M, Marino M, Brown N, Baker D, Malvem S, Hanson ME, et al. Correction of defective host response to Mycobacterium bovis BCG infection in TNF-deficient mice by bone marrow transplantation. Lab Invest. 2000; 80:901-14.
47. Ten Hove T, Van Montfrans C, Peppelenbosch M, Van Deventer S. Infliximab treatment induces apoptosis of lamina propia T lymphocytes in Cronh's disease. Gut. 2002;50:206-11.
48. Maini RN, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
49. García I, Miyazaki Y, Marchal G, Lesslauer W, Vassalli P. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-γ in the differentiation of protective granulomas. Eur J Immunol. 1997;27:3182-90.
50. Scallon B, Moore M, Trinh H, Knight D, Ghrayeb J. Chimeric anti-TNF-alfa monoclonal antibody cA2 binds recombinant transmembrane TNF-alfa and activates immune effector functions. Cytokine. 1995;7:251-9.
51. Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Álvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003;30:1436-9.
52. ATS, CDC, IDSA. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S47.
53. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montera MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7.
54. Lipsky P, St. Clair W, Furst D, Breedveld F, Smolen J, Kalden JR, et al. 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade®) in patients with active rheumatoid arthritis despite methotrexate. Arthritis Rheum. 1999;42:S1980.
55. Saito H, Miyata M, Ito M, Katakura K, Shishido H, Orikasa H, et al. Rhabdomyolysis and aggravation of arthritis in a rheumatoid arthritis patient as a result of sepsis due to Staphylococcus aureus infection of a rheumatoid nodule; a catastrophic outcome. J Med Sci. 1999;342:763-9.
56. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653-6.
57. Pérez-García C, Maymó-Guarch J, Benito-Ruiz P. Influencia del inftiximab en la resistencia antimicrobiana. Rev Esp Reumatol. 2002;1:61-9.
58. Kolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax. 2001;56:121-5.
59. Flood DA, Chan CK, Pruzanski W. Pneumocystis carinii pneumoniae associated with methotrexate therapy in rheumatoid arthritis. J Rheumatol (Canada). 1991;18:1254-56.
60. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47:628-33.
61. Salaffi F, Manganelli P, Carotti M, Le Mense GP, Sahn SA, Hargreaves MR, et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol (Belgium). 1997;16:296-304.
62. Sandborn WJ. Steroid-dependent Crohn's disease. Can J Gastroenterol. 2000;14 Suppl C:17-22.
63. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol. 2000;95:841-2.
64. Kavanaugh A, Schaible T, DeWoody K, Marsters P, Dittrich K, Harriman G. Long-term follow-up of patients treated with infliximab (anti-TNF antibody) in clinical trials. Arthritis Rheum. 1999;42:S1979.
65. Roux N, Flipo RM, Cortet B, Hargreaves MR, Mowat AG, Benson MK, et al. Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. Rev Rheum Engl Ed. 1996;63:453-6.
66. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099-100.
67. Griffin SP, Selby WS. Poor wound healing following surgery in three patients who received infliximab for Crohn's disease. J Gastroenterol Hepatol. 2000. p. 15.